Next Article in Journal
Sex-Specific Responses of Sexual Reproduction, Clonal Reproduction, and Vegetative Growth to Environmental (Biotic and Abiotic) Factors in the Clonal Dioecious Plant Acer barbinerve
Next Article in Special Issue
Tocopherol and Tocotrienol Content in the Leaves of the Genus Hypericum: Impact of Species and Drying Technique
Previous Article in Journal
Flowering Synchronization Using Artificial Light Control for Crossbreeding Hemp (Cannabis sativa L.) with Varied Flowering Times
Previous Article in Special Issue
A Comprehensive Review on Graptopetalum paraguayense’s Phytochemical Profiles, Pharmacological Activities, and Development as a Functional Food
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Phytochemical Investigation of Chamaemelum nobile L. and Evaluation of Acetylcholinesterase and Tyrosinase Inhibitory Activity

by
Luciana Maria Polcaro
1,2,
Antonietta Cerulli
1,
Milena Masullo
1,* and
Sonia Piacente
1,3
1
Dipartimento di Farmacia, Università degli Studi di Salerno, Via Giovanni Paolo II n. 132, 84084 Fisciano, Italy
2
Ph.D. Program in Drug Discovery and Development, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy
3
National Biodiversity Future Center (NBFC), 90133 Palermo, Italy
*
Author to whom correspondence should be addressed.
Plants 2025, 14(4), 595; https://doi.org/10.3390/plants14040595
Submission received: 20 January 2025 / Revised: 8 February 2025 / Accepted: 12 February 2025 / Published: 15 February 2025
(This article belongs to the Special Issue Bio-Active Compounds in Horticultural Plants)

Abstract

:
The ageing of the world population has led to an increase in the incidence of neurodegenerative diseases. In this regard, plants have become an important source of bioactive principles that are able to act on multiple targets. Chamaemelum nobile (L.) All. is a perennial herb of the Asteraceae family, known as Roman chamomile, less studied in the scientific literature than the more common Matricaria chamomilla. Flavonoids and sesquiterpene lactones represent the main secondary metabolites. Among these, nobilin and its derivatives are considered the main components. With the aim of performing a phytochemical investigation, the extract of the fresh aerial parts of C. nobile was firstly analysed by LC-(+)ESI/QExactive/MS/MS, which guided the isolation of 15 compounds (coumarins, glucoside derivatives, flavonoids, and germacrane-type sesquiterpene lactones) characterised by 1D and 2D NMR spectroscopy. The presence of a derivative of nobilin, never been reported before, was highlighted. Moreover, for all isolated compounds, acetylcholinesterase and tyrosinase inhibitory activity were tested by spectrophotometric assays. The results showed that the tested compounds presented interesting tyrosinase (IC50 values: 32.09–412.02 µM) and acetylcholinesterase inhibitory activity (IC50 values: 181.58–387.99 µM). In detail, apigenin 7-O-rutinoside (6) showed the highest tyrosinase and AchE inhibitory activity, with IC50 values of 32.09 and 181.58 µM, respectively.

1. Introduction

Chamomile is indeed a plant with a long history of use, particularly for its medicinal properties. The various species of chamomile, like Matricaria chamomilla (German chamomile) and Chamaemelum nobile (Roman chamomile), have been valued for their calming effects and their ability to treat a range of ailments, from digestive issues to skin irritations. The ancient Egyptians’ reverence for chamomile reflects its importance in their medicinal practices [1]. The plant association with the Sun God also underscores its symbolic importance in Egyptian culture. Chamomile popularity spread through different cultures, and its therapeutic qualities were well documented in ancient herbal texts. Today, chamomile continues to be a popular herb, often consumed as a tea, for its soothing and anti-inflammatory properties. Its gentle nature makes it a preferred remedy for stress relief, sleep problems, and minor digestive issues [2].
The two commonly used varieties with therapeutic applications, Matricaria chamomilla L. and Chamaemelum nobile L. [1], contain several classes of bioactive compounds such as triterpenoids, sesquiterpene lactones, flavonoids, coumarins, and essential oils [3]. Although M. chamomilla and C. nobile are similar in appearance, they show some differences. M. chamomilla L. has small white flowers and a yellow tubular petal at its centre. C. nobile L. contains flowers with double petals, soft stems, and has a green apple fragrance; in fact, for this reason it is also called “the apple of the ground”. In addition, it is also known as the “Physician of Plants” due to its ability to heal sick plants around it. Another difference between the two varieties is that the petals of M. chamomilla are turned down and have a raised conical centre, whereas the centre of C. nobile is flat [4]. In this work, attention was focused on Chamaemelum nobile L., a variety that has been studied less in the scientific literature. A phytochemical study was carried out with the aim of investigating the biological activity of C. nobile-specialised metabolites. The extract obtained by SLDE-Naviglio (Solid Liquid Dynamic Extraction) was analysed by high-resolution mass spectrometry (LC–ESI/HRMS) in the positive ion mode. To assign the chemical structures of the compounds detected through LC-ESI/HRMS analysis, a phytochemical investigation of the extract was conducted, leading to the isolation and structural identification of the metabolites through 1D- and 2D-NMR.
The increasing prevalence of Alzheimer’s disease (AD) and Parkinson’s disease (PD) has indeed become a major global health issue. Given the promising results from both traditional uses and scientific research, natural products continue to be an important area of focus in the development of new therapeutic agents for AD, PD, and other cognitive disorders. These compounds not only offer potential new treatments but also provide valuable leads for the design of novel drugs with fewer side effects compared to current synthetic options. Therefore, the acetylcholinesterase and tyrosinase inhibitory activity of compounds isolated from chamomile was investigated.

2. Results and Discussion

2.1. Isolation and Identification of Specialised Metabolites from C. nobile

To obtain a chromatogram which guided the isolation of specialised metabolites, C. nobile SLDE-Naviglio (50% EtOH/H2O) extract was analysed using LC-(+)ESI/QExactive/MS/MS spectrometer operating in the positive ion mode (Figure 1). In this way, it was possible to identify 15 compounds for which an accurate analysis of the fragmentation patterns was performed and is reported in Table 1.
To perform a detailed phytochemical investigation and confirm the metabolites identified by LC-ESI/HRMS analysis, the extract was fractionated on a Sephadex column, and subsequently by HPLC-UV. A total of 15 specialised metabolites (Figure 2) was isolated (Figures S1–S15). The analysis of NMR experiments (1H and 13C NMR, HSQC, HMBC, and COSY experiments) along with high-resolution MS1 and MS2 fragmentation patterns allowed us to establish their chemical structures. In detail, compound 1 belonged to coumarins; compounds 25 were characterized by a glucose moiety, and for this reason, they were grouped as glucoside derivatives. Compounds 6, 7, 9, and 15 were flavonoids, while compounds 8 and 1014 were elucidated as germacrane-type sesquiterpene lactones. To the best of our knowledge, compounds 35 and 7 were herein reported for the first time in C. nobile and the Asteraceae family. Noteworthy, compound 13 was a derivative of nobilin, never reported before.

2.2. Characterisation of 11,13-Dihydro-8-Tigloylhydroxyisonobilin (13)

The HRMS of compound 13 (m/z 387.1806 [M + Na]+ calculated for C20H28O6Na, 387.1784) and the 13C NMR data supported the molecular formula C20H28O6. The MS/MS spectrum of this compound showed a product ion at m/z 287.1254 [M + Na]+ (C15H20O4Na), corresponding to the neutral loss of 100 Da attributed to a tigloyl moiety (C5H8O2). The 1H NMR spectrum showed characteristic signals for two exomethylene protons at δ 5.55 and 5.49 (each, 1H, d, J = 0.5 Hz), one olefinic proton at δ 5.30 (m), four oxygen-bearing methine protons at δ 6.14 (1H, dd, J = 9.4, 7.8 Hz), δ 5.31 (1H, m), δ 3.93 (1H, brdd, 9.5, 5.8), δ 4.47 (1H, brt, J = 4.4 Hz), a secondary methyl group at δ 1.30 (3H, d, J = 6.8 Hz), and a tertiary methyl group at δ 1.83 (1H, s). These data, along with the analysis of 2D NMR data (HSQC, HMBC, and COSY), resembled the structure of a germacranolide skeleton similar to hydroxyisonobilin (10) [5], except for the replacement of an exomethylene group with a secondary methyl group (δ 1.30, Me-13). The configuration of the methyl group at C-11 was deduced to be β according to the trans diaxial coupling constant between H-7 and H-11 (J = 12.3 Hz) [6]. The NMR values and the proton coupling constant confirmed the same relative stereochemistry reported for hydroxyisonobilin (10) [5] (Table 2). In detail, the stereochemistry at C-l was supported by the coupling constants of H-1 (J = 9.5, 5.8 Hz) which indicated a β orientation for the hydroxy function [5]; the β-orientation of the C-3 hydroxy function was established on the basis of the coupling constant of H-3 (brt, J = 4.4 Hz) compared with that reported by De Mieri et al. [5], and the proton coupling constant of H-6 (dd, J = 9.4, 7.8) suggested the trans-fusion of the lactonic ring, as described for analogue sesquiterpene lactones [7,8].
Moreover, in the 1H NMR spectrum, signals at δ 6.22 (1H, brdd, J = 7.3, 1.3 Hz), δ 2.03 (3H, d, J = 7.3 Hz), and δ 1.94 (3H, brd, J = 1.3 Hz), corresponding to a tigloyl moiety, were evident. The HMBC correlation between H-8 (δ 5.31) with a carbon resonance at δ 167.3 revealed the linkage of the tigloyl moiety at C-8 of the germacranolide skeleton. Based on these results, compound 13 was identified as 11,13-dihydro-8-tigloylhydroxyisonobilin, which had never been reported before in the literature. 1H NMR, HSQC, HMBC, COSY, 13C NMR, and ESI-MS spectra of compound 13 have been reported in Figures S15–S20.

2.3. Tyrosinase Inhibition

The prevalence of neurocognitive disorders increases every year as the population continues to age. One of the most common neurodegenerative diseases is Parkinson’s disease (PD). Tyrosinase is one of enzyme involved in neuromelanin biosynthesis in the brain, where elevated tyrosinase activity may cause high dopamine production and, consequently, high neuromelanin production (NM) [9]. The neuromelanin accumulation disrupts neuronal proteostasis and may produce α-synuclein aggregation and PD progression. Indeed, it is well established that PD is characterised by the selective degeneration of neurons containing NM, particularly in the substantia nigra pars compacta (SNpc), leading to the hallmark motor symptoms of PD [9]. Following this evidence and considering the traditional medicinal uses of chamomile, such as inducing calmness and relaxation [3], in our ongoing investigation on tyrosinase inhibitory activity of C. nobile green extracts [10], for all isolated compounds, a tyrosinase inhibition assay was performed. As reported in Figure 3, flavonoids 6, 7, and 9 and scopolin 1 showed the highest inhibition, with IC50 values in a range of 32.09–50.84 μM, better than the kojic acid (65.53 μM) used as positive control. Apigenin (9), considered a chamomile marker [10], reported in the literature to be a natural tyrosinase inhibitor [1], showed high inhibition with IC50 = 50.84 µM. For the glucoside derivatives (compounds 25), tested for the first time, the range of tyrosinase inhibition was 191.89–412.02 μM in terms of IC50 values. Finally, germacrane-type sesquiterpene lactones, never tested before against tyrosinase, showed IC50 values ranging from 145.83 to 314.10 μM, with 11,13 dihydro-8-tigloylhydroxyisonobilin (13) exhibiting the highest activity (IC50 = 145.83 µM) (Table S1).

2.4. Evaluation of the Inhibition Kinetic of Compound 13

With the aim of understanding the type of inhibition of 11,13 dihydro-8-tigloylhydroxyisonobilin (13), the most active compound belonging to the class of germacrane-type sesquiterpene lactones, a kinetic study was performed. Figure 4 shows a Lineweaver–Burk double reciprocal plot for the inhibition of 13 on tyrosinase enzyme, defining uncompetitive inhibition. The maximum velocity (Vmax) value was determined as 42.02 µM/min and the Michaelis–Menten constant (Km) as 0.11 mM for L-tyrosine. The presence of compound 13 decreased the Vmax value to 27.25 µM/min and the Km value to 0.07 mM. These data indicated that compound 13 inhibited tyrosinase in an uncompetitive manner.

2.5. Acetylcholinesterase Inhibition Assay Results

Another common neurodegenerative disease is Alzheimer’s disease (AD). The main histopathological features of AD are neurofibrillary tangles (NFTs) and senile plaques, consisting of protein aggregates of the hyperphosphorylated tau protein and amyloid β (Aβ) [11]. The degeneration or atrophy of cholinergic neurons in the basal forebrain are responsible for the constant cholinergic deficit. In addition, there is a strong decrease in the neurotransmitter acetylcholine (ACh). Therefore, one therapeutic hypothesis has been to try to restore the physiological levels of ACh. Considering this, physiologically, the AChE enzyme acts by hydrolysing the neurotransmitter ACh, and the inhibition of this enzyme increases the amount of ACh present in the inter-synaptic space. Therefore, AChE inhibitors can improve cholinergic transmission by limiting the degradation of ACh. Interestingly, two of the few drugs currently licensed in Europe to alleviate cognitive symptoms in AD, galantamine and rivastigmine, are derived from natural sources. Galantamine is obtained from the bulbs of certain plants, such as Narcissus species (daffodils) and rivastigmine is derived from the Alstonia tree. Both drugs are acetylcholinesterase inhibitors, working by increasing acetylcholine levels in the brain to help alleviate the cognitive deficits seen in AD. This highlights the ongoing importance of natural products in the search for new treatments for cognitive disorders [12].
Several classes of specialised metabolites from plants have shown the ability to inhibit AChE, including coumarins, terpenes, flavonoids, glycosides, and polyphenols [13]. A large number of flavonoids (such as apigenin, biochanin, naringin, genistein, quercetin, rutin, diosmin, kaempferol-3-O-galactoside, luteolin-7-O-rutinoside, silibinin, kaempferol, quercitrin, myricetin, perlargonidin, cyanidin, epigallocatechin gallate, and chrysin) have been tested for their possible AChE inhibition, demonstrating that they possess an exceptional preclinical efficacy [14]. Also, sesquiterpene lactones have been shown to modulate cholinergic transmission by inhibiting AchE [15]. In the literature, in the last decade, multiple sesquiterpenes have been reported to possess AChE inhibitory activity [16,17,18]. As reported by Elsebay et Al., sesquiterpene lactones like amberboin and lipidiol, isolated from Volutaria abyssinica A. Rich (Asteraceae), inhibited AchE more than galantamine used as a reference compound [19].
For these reasons, all the metabolites isolated from C. nobile were evaluated for their inhibition ability against the AChE enzyme. As shown in Figure 5, apigenin 7-O-rutinoside (6) showed the highest AchE inhibitory activity with an IC50 value of 181.58 µM, followed by compound 15 (5,7-dihydroxy-6-methoxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one), herein tested for the first time, with an IC50 value of 189.82 µM. Also, scopolin (coumarin derivative, compound 1) showed high inhibitory activity, with IC50 = 231.25 µM. All the germacrane-type sesquiterpene lactones, herein tested for the first time, demonstrated AChE inhibitory activity, with IC50 values in a range from 224.78 (8) to 303.71 (14) µM; 11,13 dihydro-8-tigloylhydroxyisonobilin (13) exhibited an IC50 value of 244.74 µM (Table S2).

3. Materials and Methods

3.1. Reagent and Solvents

MeOH and H2O for HPLC were purchased from VWR (Milan, Italy). CH3CN, HCOOH, and H2O for LC-MS analysis were purchased from Merck (Milan, Italy). MeOH-d4 (99.95%), tyrosinase enzyme from mushroom (Agaricus bisporus), kojic acid, L-tyrosine, acetylcholinesterase from Electrophorus electricus (electric eel), acetylthiocholine chloride, 5′,5′-Dithiobis-2-Nitrobenzoic Acid (DTNB), and galantamine hydrobromide were purchased from Sigma-Aldrich (Milan, Italy).

3.2. Sample Preparation and Extraction

Fresh plants of Chamaemelum nobile L. (aerial parts) were provided by the Fitomedical company (Binasco, MI, Italy), which purchased them from Azienda Agricola Bio Il Ramerino, Pitigliano (GR), a certified company in the cultivation of officinal plants [10]. The plant was cut to increase the solvent–drug contact surface, and the water content already present in the fresh plant was evaluated by calculating the dry yield. Then, it was extracted through the non-conventional extraction technique, SLDE-Naviglio, with a final mixture of 50% EtOH/H2O.

3.3. UPLC-HRMSMS Analysis

To obtain a chromatogram which guided the phytochemical study and the isolation of specialised metabolites, the extract was analysed using liquid chromatography coupled with electrospray ionisation and a high-resolution mass spectrometer (QExactive: hybrid Quadrupole-Orbitrap Mass Spectrometer, Thermo Fischer, Waltham, MA, USA), operating in the positive ion mode (for more details, see the Supporting Materials).

3.4. Isolation of Specialised Metabolites

C. nobile extract obtained via SLDE-Naviglio, using a 50% EtOH/H2O solution (3 g), was vacuum-dried and subjected to size exclusion chromatography on Sephadex LH-20 (25–100 μm, GE Healthcare Bio Sciences AB, Uppsala, Sweden), eluted with MeOH at a constant flow rate of 1.2 mL/min. The size of the column used was 100 × 5 cm. A total of 50 fractions were obtained and monitored by TLC (Thin Layer Chromatography). Fractions 49–50 (9.8 mg) corresponded to pure compound 9 (apigenin).
For the other fractions dissolved in MeOH (10 mg/100 μL), further purification using an RP-HPLC-UV system (Agilent Technologies 1260 Infinity, Milan, Italy) was necessary. The wavelength was set to 254 nm. The mobile phase consisted of solvent A (H2O + 0.1% formic acid) and solvent B (CH3CN + 0.1% formic acid) at a flow rate of 2 mL/min. A Sinergi 10u-Hydro RP 80A column (250 × 10.00 μm) was used. The HPLC gradient was as follows: 0–5 min from 5% to 25% B, 5–10 min from 25% to 40% B, 10–30 min from 40% to 60% B, 30–40 min from 60% to 90% B, 40–50 min from 90% to 100% B, and for 50–60 min, it was held at 100% for 5 min before returning to the starting percentage. Fraction 18 (99.5 mg) was purified to obtain compounds 4 (1.8 mg, Rt = 11.2 min), 5 (1.4 mg, Rt = 13.5 min), 10 (1.7 mg, Rt = 36.6 min), 12 (1.0 mg, Rt = 31.6 min), and the new compound 13 (1.3 mg, Rt = 37.8). Fraction 19 (108.7 mg) was chromatographed to obtain compounds 2 (0.9 mg, Rt = 15.6 min), 8 (0.8 mg, Rt = 35.4), 11 (0.8 mg, Rt = 34.9 min), and 14 (1.1 mg, Rt = 51.6). Fractions 20–21 (36.3 mg) were purified to obtain compound 3 (0.7 mg, Rt = 23.2 min). Fractions 22–29 (87.4 mg) were chromatographed to obtain compound 1 (0.4 mg, Rt = 15.2). Fractions 30–34 (53.7 mg) were purified to obtain compounds 6 (1.8 mg, Rt = 20.1 min) and 7 (1.2 mg, Rt = 24.6 min). Fractions 35–48 (67.1 mg) were purified to obtain compound 15 (0.7 mg, Rt = 48.3 min).
11,13 dihydro-8-tigloylhydroxyisonobilin (13): white solid, [α]D25-100.00 (c 0.1, MeOH); IR (KBr) νmax 3420, 1750, 1660, cm−1; for 1H NMR and 13C NMR data, see Table 2; HRESIMS m/z 387.1806 [M + Na]+ (calcd C20H28O6Na, 387.1784).

3.5. 1D and 2D NMR Analysis

For the characterisation of all isolated compounds, 1D and 2D NMR analyses were performed. For each sample, 1H NMR, HSQC, HMBC, and COSY spectra were acquired. For compound 13, 13C NMR spectrum was carried out (for more details, see the Supporting Materials in the section General Experimental Procedures).

3.6. Tyrosinase Inhibition Assay

The tyrosinase inhibitory activity was evaluated using a method previously described [20,21] with slight modification (for details, see the Supporting Materials).

3.7. Tyrosinase Inhibition Kinetics Study

Kinetic analysis of the tyrosinase enzyme for compound 13 was carried out using the Lineweaver–Burk double reciprocal plot. The experiment was conducted at a constant enzyme concentration (100 U/mL mushroom tyrosinase) and different L-tyrosine concentrations (1, 0.5, 0.25, and 0.125 mM) in the absence (negative control) and the presence of the inhibitor (30 µL at a final concentration of 53.52 µg/mL). At 37 °C, the enzyme inhibition reaction was recorded by measuring the absorbance of the microplate reader at 495 nm for 0, 3, 6, 9, 12, and 15 min. The data obtained were plotted as 1/change in absorbance of the product (1/V) against the 1/substrate concentration (1/[S]) and Vmax and Km were calculated using the following equations: Y = 0.0026X + 0.0238 and R2 = 0.9996 for the control, and Y = 0.0025X + 0.0367 and R2 = 0.9927 for the inhibitor (compound 13).

3.8. Acetylcholinesterase Inhibition Assay

The acetylcholinesterase (AchE) inhibitory activity was evaluated using a method described by Balkrishna et al. [22] with slight modification (for details, see the Supporting Materials).

4. Conclusions

In this work, attention was focused on Chamaemelum nobile L., a variety that has been little studied in the scientific literature. After a phytochemical investigation that led to the isolation of a never-reported sesquiterpene lactone, the potential CNS biological activity was evaluated for all 15 isolated compounds. Regarding the tyrosinase inhibitory activity, apigenin, apigenin 7-O-rutinoside, camaraside (flavonoids), and scopolin (coumarin derivative) showed the highest inhibition with IC50 values ranging from 32.09 to 50.84 µM. Regarding AchE inhibitory activity, the compound that showed the highest activity was 5,7-dihydroxy-6-methoxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one, tested herein for the first time.
For a compound to be considered a potential therapeutic agent for Alzheimer’s disease (AD), one of the crucial factors is its ability to cross the blood–brain barrier (BBB) [15]. Their lipophilic nature allows sesquiterpenes to interact favourably with the lipid components of the BBB, facilitating their ability to cross it. Indeed, several studies, including in silico (computer-based) modelling, simulate how molecules interact with the BBB and cross biological membranes by passive diffusion transport [23]; in addition, within in vivo models, some of these terpenoid derivatives have demonstrated the ability to reach the CNS, highlighting their potential as therapeutic agents for AD and other neurological conditions [23].
Considering flavonoids, within the subclass of flavones (of which apigenin is a part), the flavone aglycons have been shown to have the ability to pass across the BBB [23,24]. Therefore, the specialised metabolites isolated from C. nobile may be interesting candidates for further studies on their potential activities on the central nervous system.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/plants14040595/s1, Figures S1–S14: 1H NMR spectra (600 MHz, CD3OD) of compound 112, 14, and 15; Figures S15–S19: 1H NMR, HSQC, HMBC, COSY, and 13C NMR spectra (600 MHz, CD3OD) of compound 13; Figure S20: ESI-MS of compound 13, Table S1: Tyrosinase inhibition activity of specialised metabolites isolated from C. nobile, Table S2: AchE inhibition activity of specialised metabolites isolated from C. nobile.

Author Contributions

Conceptualisation, L.M.P. and M.M.; methodology, L.M.P. and A.C.; software, A.C. and L.M.P.; validation, M.M., S.P. and L.M.P.; data curation, M.M.; writing—original draft preparation, S.P.; writing—review and editing, M.M. and L.M.P.; visualisation, M.M.; supervision, S.P.; project administration, S.P.; funding acquisition, S.P. All authors have read and agreed to the published version of the manuscript.

Funding

This project was funded under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.4—Call for tender No. 3138 of 16 December 2021, rectified by Decree n.3175 of 18 December 2021 of the Italian Ministry of University and Research funded by the European Union—NextGenerationEU; Award Number: Project code CN_00000033, Concession Decree No. 1034 of 17 June 2022 adopted by the Italian Ministry of University and Research, CUP: D43C22001260001, Project title “National Biodiversity Future Center—NBFC”.

Data Availability Statement

The data presented in this study are available in the main article and in the Supplementary Materials.

Acknowledgments

The authors would like to thank the Fitomedical company for providing chamomile and the National Biodiversity Future Centre.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Sah, A.; Naseef, P.P.; Kuruniyan, M.S.; Jain, G.K.; Zakir, F.; Aggarwal, G. A Comprehensive Study of Therapeutic Applications of Chamomile. Pharmaceuticals 2022, 15, 1284. [Google Scholar] [CrossRef] [PubMed]
  2. Salamon, I. The Slovak gene pool of German chamomile (Matricaria recutita L.) and comparison in its parameters. Pharmaceuticals 2018, 31, 70–75. [Google Scholar]
  3. Srivastava, J.K.; Shankar, E.; Gupta, S. Chamomile: A herbal medicine of the past with bright future. Mol. Med. Rep. 2010, 3, 895–901. [Google Scholar]
  4. Dai, Y.-L.; Li, Y.; Wang, Q.; Niu, F.-J.; Li, K.-W.; Wang, Y.-Y.; Wang, J.; Zhou, C.-Z.; Gao, L.-N. Chamomile: A Review of Its Traditional Uses, Chemical Constituents, Pharmacological Activities and Quality Control Studies. Molecules 2023, 28, 133. [Google Scholar] [CrossRef] [PubMed]
  5. De Mieri, M.; Monteleone, G.; Ismajili, I.; Kaiser, M.; Hamburger, M. Antiprotozoal Activity-Based Profiling of a Dichloromethane Extract from Anthemis nobilis Flowers. J. Nat. Prod. 2017, 80, 459–470. [Google Scholar] [CrossRef]
  6. Zaiter, L.; Bouheroum, M.; Benayache, S.; Benayache, F.; León, F.; Brouard, I.; Quintana, J.; Estévez, F.; Bermejo, J. Sesquiterpene lactones and other constituents from Matricaria chamomilla L. Biochem. Syst. Ecol. 2007, 35, 533–538. [Google Scholar] [CrossRef]
  7. Abdel-Mogib, M.; Jakupovic, J.; Dawidar, A.M.; Metwally, M.A.; Abou-Elzahab, M. Glaucolides from Achillea fragrantissima. Phytochemistry 1989, 28, 3528–3530. [Google Scholar] [CrossRef]
  8. Zarga, M.A.; Qauasmeh, R.; Sabri, S.; Munsoor, M.; Abdalla, S. Chemical Constituents of Artemisia arborescens and the Effect of the Aqueous Extract on Rat Isolated Smooth Muscle. Planta Med. 1995, 61, 242–245. [Google Scholar] [CrossRef]
  9. Gonzalez-Sepulveda, M.; Compte, J.; Cuadros, T.; Nicolau, A.; Guillard-Sirieix, C.; Peñuelas, N.; Lorente-Picon, M.; Parent, A.; Romero-Giménez, J.; Cladera-Sastre, J.M.; et al. In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson’s disease. Brain 2023, 146, 1040–1052. [Google Scholar] [CrossRef]
  10. Polcaro, L.M.; Cerulli, A.; Montella, F.; Ciaglia, E.; Masullo, M.; Piacente, S. Chemical Profile and Antioxidant and Tyrosinase Inhibitory Activity of Chamaemelum nobile L. Green Extracts. Cosmetics 2024, 11, 94. [Google Scholar] [CrossRef]
  11. Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011, 1, a006189. [Google Scholar] [CrossRef] [PubMed]
  12. Goyal, R.; Mittal, P.; Gautam, R.K.; Kamal, M.A.; Perveen, A.; Garg, V.; Alexiou, A.; Saboor, M.; Haque, S.; Farhana, A.; et al. Natural products in the management of neurodegenerative diseases. Nutr. Metab. 2024, 21, 26. [Google Scholar] [CrossRef] [PubMed]
  13. Santos, T.C.D.; Gomes, T.M.; Pinto, B.A.S.; Camara, A.L.; Paes, A.M.D.A. Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer’s Disease Therapy. Front. Pharmacol. 2018, 9, 1192. [Google Scholar] [CrossRef]
  14. Khan, H.; Marya; Amin, S.; Kamal, M.A.; Patel, S. Flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects. Biomed. Pharmacother. 2018, 101, 860–870. [Google Scholar]
  15. Arya, A.; Chahal, R.; Rao, R.; Rahman, H.; Kaushik, D.; Akhtar, M.F.; Saleem, A.; Khalifa, S.M.A.; El-Seedi, H.R.; Kamel, M.; et al. Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy. Biomolecules 2021, 11, 350. [Google Scholar] [CrossRef] [PubMed]
  16. Hegazy, M.E.F.; Ibrahim, A.Y.; Mohamed, T.A.; Shahat, A.A.; El Halawany, A.M.; Abdel-Azim, N.S.; Alsaid, M.S.; Paré, P.W. Sesquiterpene Lactones from Cynara cornigera: Acetyl Cholinesterase Inhibition and In Silico Ligand Docking. Planta Medica 2015, 82, 138–146. [Google Scholar] [PubMed]
  17. Hajimehdipoor, H.; Mosaddegh, M.; Naghibi, F.; Haeri, A.; Hamzeloo-Moghadam, M. Natural sesquiterpen lactones as acetylcholinesterase inhibitors. An. Acad. Bras. Cienc. 2014, 86, 801–806. [Google Scholar] [CrossRef]
  18. Ibrahim, M.; Farooq, T.; Hussain, N.; Hussain, A.; Gulzar, T.; Hussain, I.; Akash, M.S.H.; Rehmani, F.S. Acetyl and butyryl cholinesterase inhibitory sesquiterpene lactones from Amberboa ramosa. Chem. Cent. J. 2013, 7, 116. [Google Scholar] [CrossRef] [PubMed]
  19. Elsebai, M.F.; Ghabbour, H.A.; Marzouk, A.M.; Salmas, R.E.; Orhan, I.E.; Senol, F.S. Amberboin and lipidiol: X-ray crystalographic data, absolute configuration and inhibition of cholinesterase. Phytochem. Lett. 2018, 27, 44–48. [Google Scholar] [CrossRef]
  20. Polcaro, L.M.; Masullo, M.; Piacente, S. Effects of green extraction methods on the chemical profile of Schisandra chinensis fruit extracts and on their tyrosinase inhibitory activity. LWT 2024, 208, 116697. [Google Scholar] [CrossRef]
  21. Polcaro, L.M.; Cerulli, A.; Masullo, M.; Piacente, S. Metabolomics of Withania somnifera L. extracts by an integrated LC-MS and NMR approach and evaluation of their tyrosinase inhibitory activity. J. Pharm. Biomed. Anal. 2025, 253, 116520. [Google Scholar]
  22. Balkrishna, A.; Pokhrel, S.; Tomer, M.; Verma, S.; Kumar, A.; Nain, P.; Gupta, A.; Varshney, A. Anti-Acetylcholinesterase Activities of Mono-Herbal Extracts and Exhibited Synergistic Effects of the Phytoconstituents: A Biochemical and Computational Study. Molecules 2019, 24, 4175. [Google Scholar] [CrossRef] [PubMed]
  23. Isabel, U.-V.; Belén, A.D.L.R.M.; Elena, G.B. A new frontier in neuropharmacology: Recent progress in natural products research for blood–brain barrier crossing. Curr. Res. Biotechnol. 2024, 8, 100235. [Google Scholar] [CrossRef]
  24. Zhang, T.; Su, J.; Guo, B.; Wang, K.; Li, X.; Liang, G. Apigenin protects blood–brain barrier and ameliorates early brain injury by inhibiting TLR4-mediated inflammatory pathway in subarachnoid hemorrhage rats. Int. Immunopharmacol. 2015, 28, 79–87. [Google Scholar] [CrossRef]
Figure 1. LC–(+)ESI/QExactive/MS/MS base peak profile (in positive ion mode) of C. nobile SLDE (50% EtOH/H2O) extract. The red numbers represent the compounds identified.
Figure 1. LC–(+)ESI/QExactive/MS/MS base peak profile (in positive ion mode) of C. nobile SLDE (50% EtOH/H2O) extract. The red numbers represent the compounds identified.
Plants 14 00595 g001
Figure 2. Specialised metabolites isolated from C. nobile.
Figure 2. Specialised metabolites isolated from C. nobile.
Plants 14 00595 g002
Figure 3. Tyrosinase inhibitory activity of specialised metabolites isolated from C. nobile.
Figure 3. Tyrosinase inhibitory activity of specialised metabolites isolated from C. nobile.
Plants 14 00595 g003
Figure 4. Lineweaver−Burk plots for the inhibition of compound 13 at different concentrations of L-tyrosine (1, 0.5, 0.25, and 0.125 mM) on the tyrosinase enzyme.
Figure 4. Lineweaver−Burk plots for the inhibition of compound 13 at different concentrations of L-tyrosine (1, 0.5, 0.25, and 0.125 mM) on the tyrosinase enzyme.
Plants 14 00595 g004
Figure 5. AChE inhibition assay of specialised metabolites isolated from C. nobile.
Figure 5. AChE inhibition assay of specialised metabolites isolated from C. nobile.
Plants 14 00595 g005
Table 1. Metabolites identified in C. nobile SLDE (50% EtOH/H2O) extract by LC-(+)ESI/QExactive/MS/MS analysis.
Table 1. Metabolites identified in C. nobile SLDE (50% EtOH/H2O) extract by LC-(+)ESI/QExactive/MS/MS analysis.
Rt[M + H]+[M + Na]+Mol FormulaΔppmMS/MSName
16.97 377.0841C16H18O9−0.78359.0734 (C16H16O8Na), 215.0527 (C7H12O6Na)Scopolin
27.66 411.1619C18H28O9−1.64249.1098 (C12H18O4Na), 203.0526 (C6H12O6Na)Tuberonic acid glucoside
38.43 307.1150C14H20O6−0.93232.0700 (C11H13O4Na)Phenylethyl ꞵ-D-glucopyranoside
48.56195.0875 C7H14O62.38nf1-Methylpropyl ꞵ-D-glucopyranoside
58.97 299.1122C12H20O7−2.76nfꞵ-D-Glucopyranose, 1-[(2 Z)-2 methyl-2-butenoate]
610.33 601.1525C27H30O14−0.53331.0998 (C12H20O9Na), 167.0704 (C9H11O3)Apigenin 7-O-rutinoside
711.56493.1334 C23H24O12−1.37331.080 (C17H15O7), 316.0577 (C16H12O7)Camaraside
814.20 385.1616C20H26O6−0.59303.1209 (C15H20O5Na), 285.1098 (C15H18O4Na)8-Tigloylhydroxyisonobilin
914.52271.0595 C15H10O5−2.51119.0492 (C8H7O)Apigenin
1016.64 385.1616C20H26O6−0.72303.1209 (C15H20O5Na), 285.1098 (C15H18O4Na)Hydroxyisonobilin
1116.66 385.1619C20H26O6−0.83303.1209 (C15H20O5Na), 285.1098 (C15H18O4Na)3-Epi-hydroxyisonobilin
1217.49 383.1459C20H24O6−0.44283.0945 (C15H16O4Na), 239.1050 (C14H16O2Na)Nobilinon A
1317.85 387.1806C20H28O6−1.07287.1254 (C15H20O4Na)11,13-Dihydro-8-tigloylhydroxyisonobilin
1417.90 369.1671C20H26O50.84269.1140 (C15H18O3Na), 251.1039 (C15H16O2Na)Nobilin
1519.19315.0862 C17H14O6−1.49300.0627 (C16H12O6)5,7-Dihydroxy-6-methoxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one
Table 2. 1H and 13C NMR (600 and 150 MHz) of compound 13 in CD3OD (δ in ppm).
Table 2. 1H and 13C NMR (600 and 150 MHz) of compound 13 in CD3OD (δ in ppm).
13
δH (J in Hz)δc
13.93 (brdd, 9.5, 5.8)73.5 CH
22.28 (m), 2.25 (m)38.0 CH2
34.47 (brt, 4.4)73.0 CH
4-144.0 C
55.30 (m)125.9 CH
66.14 (dd, 9.4, 7.8)76.5 CH
72.32 (m)55.1 CH
85.31 (m)77.3 CH
92.94 (dd, 14.8, 2.3)
2.35 (m)
39.7 CH2
10-145.5 C
112.60 (dq, 12.3, 7.2)40.5 CH
12-180.0 C
131.30 (d, 6.8)16.7 CH3
145.55 (d, 0.5)
5.49 (d, 0.5)
117.8 CH2
151.83 (s)23.5 CH3
16-167.3 C
17-128.0 C
186.22 (brdd, 7.3, 1.3)139.1 CH
191.94 (brd, 1.3)20.3 CH3
202.03 (d, 7.3)15.7 CH3
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Polcaro, L.M.; Cerulli, A.; Masullo, M.; Piacente, S. Phytochemical Investigation of Chamaemelum nobile L. and Evaluation of Acetylcholinesterase and Tyrosinase Inhibitory Activity. Plants 2025, 14, 595. https://doi.org/10.3390/plants14040595

AMA Style

Polcaro LM, Cerulli A, Masullo M, Piacente S. Phytochemical Investigation of Chamaemelum nobile L. and Evaluation of Acetylcholinesterase and Tyrosinase Inhibitory Activity. Plants. 2025; 14(4):595. https://doi.org/10.3390/plants14040595

Chicago/Turabian Style

Polcaro, Luciana Maria, Antonietta Cerulli, Milena Masullo, and Sonia Piacente. 2025. "Phytochemical Investigation of Chamaemelum nobile L. and Evaluation of Acetylcholinesterase and Tyrosinase Inhibitory Activity" Plants 14, no. 4: 595. https://doi.org/10.3390/plants14040595

APA Style

Polcaro, L. M., Cerulli, A., Masullo, M., & Piacente, S. (2025). Phytochemical Investigation of Chamaemelum nobile L. and Evaluation of Acetylcholinesterase and Tyrosinase Inhibitory Activity. Plants, 14(4), 595. https://doi.org/10.3390/plants14040595

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop